MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.03 -0.49

Buy Sell

Overview

Share price change

24h

Current

Min

3.99

Max

4.05

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+225.12% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-28M 227M
Previous open	4.52
Previous close	4.03

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 sty 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 sty 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 sty 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 sty 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 sty 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 sty 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 sty 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 sty 2026, 19:38 UTC

Acquisitions, Mergers, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 sty 2026, 19:31 UTC

Earnings

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 sty 2026, 19:28 UTC

Earnings

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 sty 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 sty 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 sty 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9 sty 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9 sty 2026, 17:05 UTC

Earnings

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 sty 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

225.12% upside

12 Months Forecast

Average 13.2 USD 225.12%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.